Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: Produces stable disease but at the cost of high toxicity

Research output: Contribution to journalLetterpeer-review

6 Scopus citations
Original languageEnglish (US)
Pages (from-to)1789-1791
Number of pages3
JournalLeukemia
Volume27
Issue number8
DOIs
StatePublished - Aug 2013

Bibliographical note

Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.

Cite this